Kate Vandyke
Kate Vandyke
Post-doctoral Research Fellow, University of Adelaide
Verified email at adelaide.edu.au
Title
Cited by
Cited by
Year
Dysregulation of bone remodeling by imatinib mesylate
K Vandyke, S Fitter, AL Dewar, TP Hughes, ACW Zannettino
Blood 115 (4), 766-774, 2010
1322010
N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer
KM Mrozik, OW Blaschuk, CM Cheong, ACW Zannettino, K Vandyke
BMC cancer 18 (1), 939, 2018
802018
The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo
K Vandyke, AL Dewar, P Diamond, S Fitter, CG Schultz, NA Sims, ...
Journal of Bone and Mineral Research 25 (8), 1759-1770, 2010
802010
Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion
S Fitter, K Vandyke, S Gronthos, ACW Zannettino
Journal of molecular endocrinology 48 (3), 229-240, 2012
582012
SAMSN1 is a tumor suppressor gene in multiple myeloma
JE Noll, DR Hewett, SA Williams, K Vandyke, C Kok, LB To, ...
Neoplasia 16 (7), 572-585, 2014
552014
Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis
K Vandyke, AL Dewar, AN Farrugia, S Fitter, LB To, TP Hughes, ...
Leukemia 23 (5), 994-997, 2009
542009
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML …
S Fitter, K Vandyke, CG Schultz, D White, TP Hughes, ACW Zannettino
The Journal of Clinical Endocrinology & Metabolism 95 (8), 3763-3767, 2010
452010
EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair
A Arthur, RA Panagopoulos, L Cooper, D Menicanin, IH Parkinson, ...
Journal of Bone and Mineral Research 28 (4), 926-935, 2013
422013
Imatinib mesylate causes growth plate closure in vivo
K Vandyke, AL Dewar, S Fitter, D Menicanin, LB To, TP Hughes, ...
Leukemia 23 (11), 2155-2159, 2009
412009
Circulating N‐cadherin levels are a negative prognostic indicator in patients with multiple myeloma
K Vandyke, AWS Chow, SA Williams, LB To, ACW Zannettino
British journal of haematology 161 (4), 499-507, 2013
342013
EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling
S Hemming, D Cakouros, J Codrington, K Vandyke, A Arthur, ...
The FASEB Journal 31 (3), 1011-1027, 2017
312017
Therapeutic targeting of N‐cadherin is an effective treatment for multiple myeloma
KM Mrozik, CM Cheong, D Hewett, AWS Chow, OW Blaschuk, ...
British Journal of Haematology 171 (3), 387-399, 2015
302015
Identification of novel EZH2 targets regulating osteogenic differentiation in mesenchymal stem cells
S Hemming, D Cakouros, K Vandyke, MJ Davis, ACW Zannettino, ...
Stem cells and development 25 (12), 909-921, 2016
292016
PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma
JE Noll, K Vandyke, DR Hewett, KM Mrozik, RJ Bala, SA Williams, CH Kok, ...
Journal of hematology & oncology 8 (1), 1-16, 2015
292015
Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress
CT Wallington-Beddoe, MK Bennett, K Vandyke, L Davies, JR Zebol, ...
Oncotarget 8 (27), 43602, 2017
262017
HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1
K Vandyke, MN Zeissig, DR Hewett, SK Martin, KM Mrozik, CM Cheong, ...
Cancer Research 77 (20), 5452-5463, 2017
252017
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
ZY Gan, S Fitter, K Vandyke, LB To, ACW Zannettino, SK Martin
European journal of haematology 94 (4), 343-354, 2015
252015
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects
K Vandyke, S Fitter, J Drew, S Fukumoto, CG Schultz, NA Sims, DT Yeung, ...
The Journal of Clinical Endocrinology & Metabolism 98 (1), 67-76, 2013
242013
Immunomodulatory properties of induced pluripotent stem cell‐derived mesenchymal cells
J Ng, K Hynes, G White, KN Sivanathan, K Vandyke, PM Bartold, ...
Journal of cellular biochemistry 117 (12), 2844-2853, 2016
232016
Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo
CM Cheong, AWS Chow, S Fitter, DR Hewett, SK Martin, SA Williams, ...
Experimental Cell Research 332 (1), 24-38, 2015
222015
The system can't perform the operation now. Try again later.
Articles 1–20